Pages that link to "Q35878459"
Jump to navigation
Jump to search
The following pages link to Cardiotoxicity of molecularly targeted agents (Q35878459):
Displaying 12 items.
- Vascular Complications of Cancer Chemotherapy (Q26766269) (← links)
- Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial (Q34011870) (← links)
- A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. (Q34143251) (← links)
- Lifestyle interventions for cardiovascular risk reduction in women with breast cancer (Q35878469) (← links)
- Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox. (Q38163389) (← links)
- Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature (Q38883187) (← links)
- Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies (Q39461781) (← links)
- Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). (Q40218182) (← links)
- Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights (Q49315568) (← links)
- Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (Q50504945) (← links)
- 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers (Q51066704) (← links)
- A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic (Q91760286) (← links)